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use	 and	 correlates	 of	 AHM	 use	 during	months	 7-12	 post-transplant.	 For	 patients	
filling	AHMs,	 individual	agents	used	included:	dihydropyridine	(DHP)	CCBs,	55.6%;	






for	 the	 general	 population,	KTx	 recipients	 are	prescribed	 relatively	more	BBs	 and	
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1  | INTRODUC TION
Hypertension	 is	 a	 highly	 prevalent	 (50%-80%)	 comorbid	 condi-





determine	 the	 ideal	 blood	 pressure	management	 strategy	 for	KTx	
patients,	primarily	focused	on	the	use	of	angiotensin-converting-en-
zyme	 inhibitors/angiotensin	 II	 receptor	 blockers	 (ACEi/ARBs)	 and	
calcium	 channel	 blockers	 (CCBs).5	 However,	 the	 optimal	 medical	
regimen	 in	 this	 population	 remains	 undefined.	 Factors	 to	 be	 con-
sidered	 in	prescribing	AHMs	 include	comorbid	conditions	 that	are	
indications	for	particular	agents,6	or	drug	interactions	with	immuno-
suppressive	therapy.7
In	 a	 cohort	 of	 16	157	KTx	 recipients,	we	previously	 examined	
AHM	use	at	the	first	transplant	anniversary	and	found	beta-block-
ers	(BBs)	to	be	the	most	commonly	used,	followed	closely	by	CCBs.8 













immunosuppressive	 regimens.	We	examined	 the	 impact	of	patient	
characteristics	and	center	effects	on	AHM	choices.	In	particular,	we	
hypothesized	 that	ACEi/ARB	use	may	have	 increased,	 and	BB	use	








Procurement	 and	 Transplantation	 Network	 (OPTN).	 The	 Health	






for	 Prescription	 Drug	 Program	 5.1-format	 prescription	 claims	 ag-
gregated	from	multiple	sources	including	data	clearinghouses,	retail	




HRSA	 approvals,	 PCD	 records	were	 linked	with	 SRTR	 records	 for	
kidney	recipients.8	Eligible	patients	had	PCD	data	during	the	period	
7-12	 months	 post-transplant.	 We	 studied	 overall	 prescribing	 pat-
terns	for	all	eligible	transplant	recipients	and	examined	variation	in	
use	of	specific	agents	among	recipients	receiving	AHMs.
2.2 | AHM regimen and covariate ascertainment
Antihypertensive	 medication	 regimens	 were	 classified	 based	 on	
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TA B L E  1  Characteristics	of	kidney	transplant	recipients	according	to	antihypertensive	medication	use	7-12	mo	after	transplant
 
DHP CCBs NDHP CCBs ACEi/ARBs BBs Diuretics Other AHMs
(N = 31 814) (N = 1699) (N = 12 082) (N = 30 196) (N = 17 126) (N = 11 479)
% % % % % %
Recipient	factors
Age,	y
19 to 30 7.6 8.6 7.1 7.2 3.8 7.5
31 to 44 19.8 22.5 20.8 20.6 15.2 20.6
45 to 59 39.6 38.0 41.3 39.5 38.9 39.9
≥60 33.0 31.0 30.9 32.7 42.1 32.0
Female 33.9 34.4 33.4 36.6 41.0 28.7
Race
White 45.8 45.4 51.5 50.8 52.7 41.6
African	American 32.7 34.6 28.1 29.7 30.9 38.2
Hispanic 14.9 15.2 14.3 13.4 11.9 14.1
Other 6.6 4.8 6.2 6.2 4.5 6.1
Body	mass	index,	kg/m2
<18.5 1.4 1.9 1.6 1.6 1.1 1.6
18.5 to <25 26.4 28.7 25.7 26.8 18.5 27.3
25 to <30 34.1 33.2 34.0 33.2 30.3 33.6
≥30 36.3 34.7 36.4 36.5 48.0 35.2
Unknown 1.8 1.6 2.3 2.0 2.1 2.4
Cause	of	ESKD
Diabetes 27.5 22.8 28.1 26.2 33.9 28.9
Glomerulonephritis 21.1 22.6 22.9 22.3 17.5 18.9
Hypertension 31.0 29.1 27.6 29.4 27.5 35.8
Polycystic	kidney	disease 8.3 9.7 10.3 8.6 9.0 6.3
Other 12.2 15.8 11.3 13.5 12.2 10.2
Comorbidities
Coronary	artery	disease 6.1 6.1 7.0 6.6 8.6 6.9
Cerebral	vascular	disease 2.7 2.0 2.5 2.7 2.9 2.8
Peripheral	vascular	disease 6.9 5.9 5.6 6.5 9.0 7.2
COPD 1.4 1.4 1.3 1.3 1.9 1.4
eGFR	at	6	mo,	mL/min	per	1.73	m2
≥60 44.2 40.8 45.0 42.0 32.2 39.3
30 to 59 48.0 50.7 48.4 49.8 54.9 50.3
<30 5.9 7.0 4.0 6.1 11.2 7.6
Missing 1.9 1.6 2.5 2.1 1.8 2.9
Donor	and	transplant	factors
Previous	transplant 11.4 15.5 10.7 13.6 13.6 12.8
Acute	rejection	at	6	months 6.3 6.6 5.5 6.5 7.6 7.0
Maintenance	ISx	regimen	at	6	mo
mTOR	inhibitor-based 4.0 4.5 5.1 4.5 7.0 6.1
Cyclosporine-based 1.3 2.9 1.6 1.3 1.9 1.6
Tac	+	MMF/MPA	+	Pred 37.0 36.6 38.7 37.6 35.5 36.8
Tac	+	MMF/MPA 13.9 13.4 15.5 13.8 13.0 12.1
(Continues)







cally	 significantly	different	 from	 the	expected	 rate	of	use	 for	 that	
regimen.
Heterogeneity	 in	 AHM	prescribing	 across	 centers	was	 quanti-
fied	using	median	odds	ratios	(MORs).	The	MOR	give	the	median	of	
the	odds	that	patients	with	identical	characteristics	will	receive	the	




the	 odds	 of	 receiving	 the	 AHM	 regimen	 of	 interest	 (BB	 or	 ACEi/
ARB)	at	one	of	 the	 randomly	selected	centers	 than	at	 the	other.16 





A	 total	 of	 147	 304	 patients	 underwent	 kidney-alone	 transplant	
between	 July	 2006	 and	 December	 2015	 (age	 >	 18	 years).	 Of	
these,	104	082	had	pharmacy	 fill	 records	 for	7-12	months	post-





had	 comorbid	 coronary	 artery,	 cerebral	 vascular	 and	 peripheral	
vascular	diseases;	and	more	commonly	received	deceased	donor	
(vs	 living	 donor)	 transplants,	 had	 acute	 rejection	 in	 the	 first	
6	months,	had	6-month	eGFR	<	60	mL/min	per	1.73	m2,	and	re-




diuretics	 (30.0%),	ACEi/ARBs	 (21.1%),	 and	other	 agents	 (20.1%).	
Diuretic	 use	 was	 more	 common	 among	 recipients	 who	 were	
older,	female,	or	obese,	with	lower	estimated	glomerular	filtration	




We	 observed	 a	 modest	 variation	 in	 use	 of	 AHM	 class	 across	
transplant	 centers,	 but	 overall	 CCBs	 and	 BBs	 remained	 the	 most	
commonly	used	AHMs	(Figure	1).	Controlling	for	demographic	and	
clinical	 factors,	 ACEi/ARB	 use	 was	 less	 likely	 in	 recipients	 with	
lower	 eGFR	 (aOR	 0.580.640.71),	 or	 of	 younger	 (<30	 years)	 or	 older	
(≥	 60	 years)	 age	 (aOR	 0.820.890.98 and 0.840.900.96,	 respectively)	





0.720.770.82)	 but	 higher	 among	 those	 using	 mTOR	 inhibitor-based	
immunosuppression	 (aOR	 1.131.271.42).	 Similarly,	 BB	 use	 was	 less	
likely	in	recipients	aged	younger	than	30	or	older	than	60	years	(aOR	
 
DHP CCBs NDHP CCBs ACEi/ARBs BBs Diuretics Other AHMs
(N = 31 814) (N = 1699) (N = 12 082) (N = 30 196) (N = 17 126) (N = 11 479)
% % % % % %
Tac,	Tac	+	Pred 8.7 7.1 7.4 8.7 8.5 8.6
Other 35.1 35.5 31.7 34.1 34.3 34.7
Donor	type
Living	donor 31.4 35.9 36.2 33.5 26.6 27.2
Standard	criteria	deceased 44.9 42.3 44.0 44.0 46.4 47.8
Expanded	criteria	deceased 12.5 10.1 10.3 11.5 15.0 13.3
Donation	after	cardiac	death 11.3 11.7 9.4 11.0 12.1 11.7
Year	of	treatment
2007 to 2013 66.3 74.2 78.8 70.5 70.8 73.2
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0.850.920.99 and 0.890.940.99,	respectively).	Regimens	containing	ACEi/
ARBs	 (aOR	 0.500.530.56)	 and	BBs	 (aOR	 0.790.820.86)	were	 filled	 less	
commonly	in	the	more	recent	study	period	of	2014-2016,	compared	
with	2007-2013	(Table	2).
In	 the	 unadjusted	 model	 addressing	 center	 effects	 alone,	 the	
MOR	for	BB	fills	was	1.55;	adding	case	factors	made	no	difference	
(Table	3),	suggesting	that	differences	in	case	factors	did	not	explain	
variation	 in	 BB	 fills	 among	 transplant	 centers.	 Similarly,	 variation	
in	ACEi/ARB	use	was	not	explained	by	differences	 in	case	factors,	
as	 the	MOR	 (1.50)	did	not	change	when	case	 factors	were	added.	








AHMs,	 followed	 by	 BBs,	 while	 ACEi/ARB	 use	 remained	 relatively	














BB	use	 in	KTx	 recipients.	The	 rationale	 for	 this	 interest	was	 low	
use	of	ACEi/ARBs	despite	the	2014	JNC-8	guidelines	recommen-
dation	 for	use	as	 first-line	agents,	and	high	 frequency	of	BB	use	
(second	 only	 to	CCBs)	 despite	 their	 being	 accorded	 a	 lower	 tier	
(second-	or	third-line)	status.6
We	 observed	 a	 48%	 reduction	 in	 ACEi/ARB	 use	 in	 the	 post-
JNC-8	era	compared	with	the	earlier	period.	This	pattern	contrasts	
with	JNC-8	recommendations	for	the	general	population	and	with	









































DHP CCBs NDHP CCBs ACEi/ARBs BBs Diurecs Other AHMs
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renal	outcomes	or	patient	 survival,	 suggesting	 that	 findings	 from	
the	 non-transplant	 population	may	 not	 extrapolate	 to	 the	 trans-
plant	population.20	Another	randomized	controlled	trial	by	Ibrahim	
et al21	 comparing	 losartan	versus	placebo	 found	no	difference	 in	
their	 primary	 outcome	 (composite	 of	 doubling	 of	 the	 fraction	 of	
renal	 cortical	 volume	 occupied	 by	 interstitium	 and	 graft	 failure	






GFR	 to	 be	 a	 problem	 despite	 very	 early	 RAAS	 blockade	 initia-






also	 reflect	 concern	 for	 side	 effects	 and	 drug	 interactions	 that	





aOR (95% CIs) aOR (95% CIs)
Recipient	factors
Age,	y
19 to 30 0.92	(0.85‒0.99)* 0.89	(0.82‒0.98)*
31 to 44 Reference Reference










18.5 to <25 Reference Reference
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TA B L E  3   (A)	Heterogeneity	in	BB	and	ACEi/ARB	use,	from	hierarchical	logistic	regression	models	adjusting	for	case-level	characteristics.	
(B)	Empirical	Bayes	estimates	for	BB	and	ACEi/ARB	use	adjusting	for	case-level	characteristics




No. of centers in 
pairwise comparison




No. of centers significantly 
below reference probability
BB	(vs	No	BB) 247 62	(25%) 47	(19%)
ACEi/ARB	(vs	no	ACEi/ARB) 247 44	(18%) 33	(13%)
Abbreviations:	ACEi/ARB,	angiotensin-converting-enzyme	inhibitor/angiotensin	II	receptor	blocker;	BB,	beta-blocker;	MOR,	median	odds	ratio.
F I G U R E  2  Center-level	variation	in	BB	and	ACEi/ARB	use	in	months	7-12	after	KTx.	ACEi,	angiotensin-converting-enzyme	inhibitor.	
AHM,	antihypertensive	medication.	ARB,	angiotensin	II	receptor	blocker.	BB,	beta-blocker;	MOR,	median	odds	ratio
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represents	 an	 actual	 improvement	 versus	 the	 vasodilatory	 prop-
erties	of	CCBs	remains	 to	be	determined.26	Common	use	of	CCBs	
in	 the	KTx	 population	may	 also	 reflect	 efficacy	 in	 reducing	 blood	




low.	Low	NDHP	CCB	use	 in	 this	population	 is	 likely	 related	to	 the	
known	interactions	with	calcineurin	inhibitors.	Lastly,	we	noted	that	
while	 some	case-level	 factors	were	associated	with	AHM	use,	 the	
variation	in	use	was	almost	entirely	driven	by	prescribing	practices	
of	 transplant	 centers.	 This	 finding	 is	 consistent	with	 our	 previous	
studies	highlighting	and	quantifying	center-level	variation	in	immu-
nosuppressive	 agent	 prescribing.9-11	 Future	 studies	 are	 needed	 to	








such	 as	 lack	of	 indication	 for	 a	 given	prescription	 and	 lack	of	 data	
on	some	granular	clinical	 factors	such	as	blood	pressure	control	or	


















is	 needed	 to	 provide	 evidence	 to	 inform	AHM	choice	 to	 optimize	
outcomes	for	KTx	recipients.27
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